Search 

Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member of Shanghai Fosun PHARMACEUNCAL (group) Co., Ltd.(Fosun Pharma”, Stock code: 600196-SH,02196-HK).

We have, by a wide margin, the safest and most effective nocturia drug. Nocturia leads to over 10,000 deaths per day and costs the US economy $215B/year in lost worktime and lower productivity.

Whale Bay & Co is a boutique financing firm focused solely on the life sciences industry. Based in Rotterdam (the Netherlands) and Basel (Switzerland) we serve SME's, investors and mid-size strategic companies in Biotech, Pharma, MedTech and Digital Health in the strategy and financial space: licensing, financing, M&A, valuation and outsources BD. We have a keen interest to expand our network and business into China. In the context of specific mandates we would like to connect with:

- pharma & medtech companies for outlicensing/JV collaborations with our clients
- investors looking for early and late stage pharma, biotech and medtech investment opportunities
- (FoF)investors interested in investment in funds

Wuxi High-tech zone is focusing on developing biopharmaceutical industry. It is one of the top high-tech zones in China. There are a number of famous biopharmaceutical companies such as AstraZeneca, Wuxi AppTech.

Eudendron is an Italian biotech company founded by Dr. Mauro Angiolini and Dr. Fabio Zuccotto. Eudendron develops anti-cancer agents for applications within the precision medicine model, adopting a tumor agnostic approach and targeting populations of patients hosting genetically defined cancers. Purpose of the company is to advance novel cancer treatments from their inception to Phase I/II. The activities of the company are also focused on the identification of novel drugs effective against protein kinase mutations responsible for clinical drug resistance. Eudendron discovered and patented a new class of highly specific inhibitors with excellent anti-cancer properties against several types of cancer cells. Patents in Europe and in USA have already been granted covering inhibitors of relevant oncology targets and their mutations. Lung and thyroid cancer, lymphoma, neuroblastoma and cutaneous cancer are diseases with unmet medical need of particular interest. Especially for neuroblastoma, the company identified drugs with a potent and specific profile. Eudendron is committed to identify Investors and/or industrial Partners to advance the pipeline programs toward the clinical stage. Basket trials will be finally designed following an agnostic clinical development.